Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00457 ...
Drug Name Prazosin
Molecular Weight 383.4011
Molecular Formula C19H21N5O4
CAS Number 19216-56-9
SMILES COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
External Links
DRUGBANK DB00457
PubChem Compound 4893
PDR 999
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 1.3 - 1.3 - https://pubchem.ncbi.nlm.nih.gov/compound/prazosin
Boiling Point 638.366 ℃ 638.366 ℃ http://www.chemspider.com/Chemical-Structure.4724.html
Melting Point 278.5 ℃ 277-280 ℃ https://www.chemicalbook.com/ChemicalProductProperty_US_CB6120870.aspx
Water Solubility 1400.0 mg/L 1.4 mg/ml https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Product_Information_Sheet/1/p7791pis.pdf
pKa 6.54 - 6.54 - https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Product_Information_Sheet/1/p7791pis.pdf

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 68.0 % 68±17 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 36.0 ng/ml 36±17 ng/ml Oral single dose; hypertension; The Pharmacological Basis of Therapeutics
T Max 3.0 h 3 h PO, oral; DRUGBANK
T Max 2.2 h 2.2±1.1 h Oral single dose; hypertension; The Pharmacological Basis of Therapeutics
Clearance 0.18 L/h/kg 3.0±0.3 ml/min/kg normal,healthy; adults; Preg, pregnant ↓ ;congestive heart disease ↓ ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Clearance 0.28 L/h/kg 4.7 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 0.60 L/kg ~0.6 L/kg DRUGBANK
Volume of Distribution 0.60 L/kg 0.60±0.13 L/kg normal,healthy; adults; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.73 L/kg 0.73 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 2.5 h ~2-3 h elimination half-life; DRUGBANK
Half-life 2.9 h 2.9±0.8 h Preg, pregnant ↑ ;congestive heart disease ↑ ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Half-life 2.0 h 2 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 1950.0 mg/kg 1950.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 102.0 mg/kg 102.0 mg/kg Intraperitoneal, IP; Rattus, Rat; DRUGBANK
Toxicity TDLo 0.29 mg/kg 285.0 ug/kg PO, oral; human, homo sapiens; DRUGBANK
Toxicity TDLo 0.0100 mg/kg 10.0 ug/kg PO, oral;  Female, women; DRUGBANK
Eliminate Route 4.0 % <4 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 97.0 % 97 % DRUGBANK
Protein Binding 85.0 % ~80-90 % DRUGBANK
Protein Binding 95.0 % 95±1 % Hepatic cirrhosis, cirr ↓ ;hypoalbuminemia Alb ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;congestive heart disease → ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 15.0 mg/day 15 mg/day PO, oral Minipress prazosin hydrochloride PDR
Max dose for children 0.4 mg/kg/day 400 mcg/kg/day PO, oral Minipress prazosin hydrochloride PDR
Max dose for adults 20.0 mg/day 20 mg/day PO, oral Minipress prazosin hydrochloride PDR
Max dose for adults 40.0 mg/day 40 mg/day PO, oral Minipress prazosin hydrochloride PDR
Max dose for adults 9.0 mg/day 9 mg/day PO, oral Minipress prazosin hydrochloride PDR
Max dose for elderly 20.0 mg/day 20 mg/day PO, oral Minipress prazosin hydrochloride PDR
Max dose for elderly 40.0 mg/day 40 mg/day PO, oral Minipress prazosin hydrochloride PDR
Max dose for elderly 9.0 mg/day 9 mg/day PO, oral Minipress prazosin hydrochloride PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1